Braveheart Bio is a late clinical-stage biotechnology company developing novel therapeutics for hypertrophic cardiomyopathy and related conditions. The company is backed by experienced life science investors including Andreessen Horowitz (a16z Bio + Health), Forbion, OrbiMed, Enavate Sciences (a platform of Patient Square Capital), and Frazier Life Sciences. Braveheart is advancing BHB-1893 through late-stage clinical development with the goal of establishing a new standard of care.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 11/05/25 | $185,000,000 | Series A |
Andreessen Horowitz Enavate Sciences Forbion Capital Partners Frazier Life Sciences OrbiMed Advisors | undisclosed |
